Profession Notes

AIBS Summit In a rare show of unity, the 57 presidents and other leaders affiliated with the 69 member societies of the American Institute of Biological Sciences (AIBS) met in Warrenton, Va., for a first-ever Presidents' Summit. They hoped to begin to generate consensus among member societies on issues related to public policy, research funding, education, and careers. According to AIBS executive director Richard O'Grady, the nonbiomedical areas of biology that the 150,000-member, 52-year-old u

Written byEugene Russo
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

AIBS Summit

In a rare show of unity, the 57 presidents and other leaders affiliated with the 69 member societies of the American Institute of Biological Sciences (AIBS) met in Warrenton, Va., for a first-ever Presidents' Summit. They hoped to begin to generate consensus among member societies on issues related to public policy, research funding, education, and careers. According to AIBS executive director Richard O'Grady, the nonbiomedical areas of biology that the 150,000-member, 52-year-old umbrella society represents have historically organized poorly as a large collective--in sharp contrast with AIBS's sister organization, the biomedical researcher-rich Federation of American Societies for Experimental Biology. Preliminary AIBS objectives include increased and diversified research funding, improved communications between biologists and the public, safeguarding science education, and increased involvement in science-based public policy. But, says O'Grady, the AIBS isn't quite ready to sponsor lobbying. "We're still trying to function together effectively on just a sort of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies